Main clinical and hematologic characteristics of 707 patients at diagnosis of PMF
| Feature . | No. . |
|---|---|
| Age, y, median (range) | 62 (11-90) |
| Sex, male/female (%) | 465/242 (66/34) |
| Spleen size* (%) | |
| No splenomegaly | 14 |
| 5 cm or less | 34 |
| 5-10 cm | 29 |
| 11-15 cm | 13 |
| More than 15 cm | 8 |
| Dupriez score, % | |
| Low | 60 |
| Intermediate | 28 |
| High | 12 |
| IPSS, % | |
| Low | 5 |
| Intermediate-1 | 30 |
| Intermediate-2 | 33 |
| High | 32 |
| Hemoglobin level, g/L† | 110 (63-149) |
| Platelet count, ×109/L† | 277 (44-990) |
| WBC count, ×109/L† | 9.0 (2.7-35.0) |
| JAK2 V617F/JAK2 wild type,‡ no. (%) | 259/157 (62/38) |
| Constitutional symptoms, (%) | 35 |
| Cardiovascular risk factors (%) | 52 |
| Smoking | 31 |
| Hypertension | 21 |
| Diabetes | 15 |
| Patients with history of thrombotic events, no. (%) | 67 (9.5) |
| AMI | 13 (1.8) |
| Stroke-TIA | 16 (2.3) |
| PAT | 2 (0.3) |
| VTE | 32 (4.5) |
| Splanchnic | 4 (0.6) |
| Cytoreductive therapy | |
| In patients with history of thrombotic events (%) | 41/67 (61) |
| In asymptomatic patients (%) | 224/640 (35) |
| Splenectomy, no. (%) | 97 (14) |
| Feature . | No. . |
|---|---|
| Age, y, median (range) | 62 (11-90) |
| Sex, male/female (%) | 465/242 (66/34) |
| Spleen size* (%) | |
| No splenomegaly | 14 |
| 5 cm or less | 34 |
| 5-10 cm | 29 |
| 11-15 cm | 13 |
| More than 15 cm | 8 |
| Dupriez score, % | |
| Low | 60 |
| Intermediate | 28 |
| High | 12 |
| IPSS, % | |
| Low | 5 |
| Intermediate-1 | 30 |
| Intermediate-2 | 33 |
| High | 32 |
| Hemoglobin level, g/L† | 110 (63-149) |
| Platelet count, ×109/L† | 277 (44-990) |
| WBC count, ×109/L† | 9.0 (2.7-35.0) |
| JAK2 V617F/JAK2 wild type,‡ no. (%) | 259/157 (62/38) |
| Constitutional symptoms, (%) | 35 |
| Cardiovascular risk factors (%) | 52 |
| Smoking | 31 |
| Hypertension | 21 |
| Diabetes | 15 |
| Patients with history of thrombotic events, no. (%) | 67 (9.5) |
| AMI | 13 (1.8) |
| Stroke-TIA | 16 (2.3) |
| PAT | 2 (0.3) |
| VTE | 32 (4.5) |
| Splanchnic | 4 (0.6) |
| Cytoreductive therapy | |
| In patients with history of thrombotic events (%) | 41/67 (61) |
| In asymptomatic patients (%) | 224/640 (35) |
| Splenectomy, no. (%) | 97 (14) |
PMF indicates primary myelofibrosis; IPSS, International Prognostic Scoring System; WBC, white blood cell; AMI, acute myocardial infarction; TIA, transient ischemic attack; PAT, peripheral arterial thrombosis; and VTE, venous thrombosis emobolism.
Below costal margin, data are available in 624 patients.
Median value (5%-95% distribution).
Test was performed on 416 patients (59%).